Seminars in Nuclear Medicine
Volume 39, Issue 6 , Pages 369-379 , November 2009

Quantitative Studies of Bone Using 99mTc-Methylene Diphosphonate Skeletal Plasma Clearance

References 

  1. Gruber R, Pietschmann P, Peterlik M. Introduction to bone development, remodelling and repair. In:  Grampp S editors. Radiology of Osteoporosis. (ed 2). Berlin, Germany: Springer; 2008;p. 1–23
  2. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone density. N Engl J Med. 2002;346:653–661
  3. Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003;18:1051–1056
  4. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350:459–468
  5. Greenspan SL, Bone HG, Ettinger MD, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: A randomised trial. Ann Intern Med. 2007;146:326–339
  6. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–1822
  7. Recker RR, Barger-Lux MJ. Bone biopsy and histomorphometry in clinical practise. In:  Favus MJ editors. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. (ed 6). Washington, DC: American Society for Bone and Mineral Research; 2006;p. 161–169
  8. Recker R, Lappe J, Davies KM, et al. Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res. 2004;19:1628–1633
  9. Camacho P, Kleerekoper M. Biochemical markers of bone turnover. In:  Favus MJ editors. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. (ed 6). Washington, DC: American Society for Bone and Mineral Research; 2006;p. 127–133
  10. Seibel MJ, Eastell R, Gundberg CM. Biochemical markers of bone metabolism. In:  Bilezikian JP,  Raisz LG,  Rodan GA editor. Principles of Bone Biology. San Diego, CA: Academic Press; 2002;p. 1543–1571
  11. Garnero P, Weichung JS, Gineyts E, et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994;79:1693–1700
  12. Beck-Jensen JE, Kollerup G, Sorensen HA, et al. A single measurement of biochemical markers of bone turnover has limited utility in the individual person. Scand J Clin Lab Invest. 1997;57:351–359
  13. Looker AC, Bauer DC, Chesnut CH, et al. Clinical use of biochemical markers of bone remodelling: Current status and future directions. Osteoporos Int. 2000;11:467–480
  14. Blake GM, Fogelman I. Monitoring treatment for osteoporosis by using bone densitometry. Semin Nucl Med. 2001;31:212–222
  15. Blake GM, Fogelman I. The role of DXA bone density scans in the diagnosis and treatment of osteoporosis. Postgrad Med J. 2007;83:509–517
  16. McClung MR, San MJ, Miller PD, et al. Opposite bone remodelling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005;165:1762–1768
  17. Boivin G, Meunier PJ. Effects of bisphosphonates on matrix mineralisation. J Musculoskelet Neuronal Interact. 2002;2:538–543
  18. Blake GM, Lewiecki EM, Kendler DL, et al. A review of strontium ranelate and its effect on DXA scans. J Clin Densitom. 2007;10:113–119
  19. Blake GM, Park-Holohan SJ, Cook GJR, et al. Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med. 2001;31:28–49
  20. Subramanian G, McAfee JG, Blair RJ, et al. Technetium-99m-methylene diphosphonate-A superior agent for skeletal imaging: Comparison with other technetium complexes. J Nucl Med. 1975;16:744–755
  21. Blau M, Ganatra R, Bender MA. 18F-fluoride for bone imaging. Semin Nucl Med. 1972;2:31–37
  22. Fogelman I, Bessent RG, Turner JG, et al. The use of whole-body retention of Tc-99m disphosphonate in the diagnosis of metabolic bone disease. J Nucl Med. 1978;19:270–275
  23. Fogelman I, Bessent RG, Cohen HN, et al. Skeletal uptake of disphosphonate (Method for prediction of postmenopausal osteoporosis). Lancet. 1980;2:667–670
  24. Fogelman I, Bessent RG, Beastall G, et al. Estimation of skeletal involvement in primary hyperparathyroidism. Ann Intern Med. 1980;92:65–67
  25. Fogelman I, Bessent R. Age-related alterations in skeletal metabolism - 24-hr whole-body retention of disphosphonate in 250 normal subjects: Concise communication. J Nucl Med. 1982;23:296–300
  26. Hyldstrup L. 24 hour whole body retention of 99mTc-methylene-diphosphonate in the assessment of bone formation (Methological evaluation, clinical applications and comparison with serum alkaline phosphatase and serum osteocalcin). Danish Med Bull. 1989;36:349–358
  27. Hyldstrup L, McNair P, Ring P, et al. Studies on diphosphonate kinetics (Part I: Evaluation of plasma elimination curves during 24 h). Eur J Nucl Med. 1987;12:581–584
  28. Blake GM, Moore AE, Park-Holohan SJ, et al. A direct in-vivo measurement of bone 99mTc-methylene diphosphonate protein binding. Nucl Med Commun. 2003;24:829–835
  29. Moore AE, Hain SF, Blake GM, et al. Validation of ultrafiltration as a method of measuring free 99mTc-MDP. J Nucl Med. 2003;44:891–897
  30. Fleming JS, Zivanovic MA, Blake GM, et al. Guidelines for the measurement of glomerular filtration rate using plasma sampling. Nucl Med Commun. 2004;25:759–769
  31. Fogelman I, Martin W. Assessment of skeletal uptake of Tc99m diphosphonate over a five-day period. Eur J Nucl Med. 1983;8:489–490
  32. Moore AE, Blake GM, Fogelman I. Quantitative measurements of bone remodelling using Tc99m methylene diphosphonate bone scans and blood sampling. J Nucl Med. 2008;49:375–382
  33. Grewal GS, Blake GM. Reference data for 51Cr-EDTA measurements of GFR derived from live kidney donors. Nucl Med Commun. 2005;26:61–65
  34. Hyldstrup L, Mogensen N, Jensen GF, et al. Urinary 99m-Tc-diphosphonate excretion as a simple method to quantify bone metabolism. Scand J Clin Lab Invest. 1984;44:105–109
  35. Thomsen K, Nilas L, Mogensen T, et al. Determination of bone turnover by urinary excretion of 99m-Tc-MDP. Eur J Nucl Med. 1986;12:342–345
  36. Davie MW, Britton JM, Haddaway M, et al. 99mTc-MDP retention in osteoporosis: Relationship to other indices of bone cell activity and response to calcium and vitamin D therapy. Eur J Nucl Med. 1987;13:462–466
  37. D'Addabbo A, Rubini G, Mele M, et al. A new method of assessing Tc99m-MDP bone uptake from a bone scan image: Quantitative measurement of radioactivity in global skeletal region of interest. Nucl Med Commun. 1992;13:55–60
  38. Brenner W, Bohuslavizki KH, Sieweke N, et al. Quantification of diphoshonate uptake based on conventional bone scanning. Eur J Nucl Med. 1997;24:1284–1290
  39. Scillitani A, Dicembrino F, Chiodini I, et al. Global skeletal uptake of Tc99m-methylene diphosphonate (GSU) in patients affected by endocrine diseases: Comparison with biochemical markers of bone turnover. Osteoporos Int. 2002;13:829–834
  40. Andrews GA, Gibbs WD, Morris AC, et al. Whole-body counting. Semin Nucl Med. 1973;3:367–388
  41. Hyldstrup L, McNair P, Transbol I. GFR-corrected 24-hour whole body retention of diphosphonate: An improved index of bone metabolism. Scand J Clin Lab Invest. 1988;48:341–345
  42. Gnanasegaran G, Moore AE, Blake GM, et al. Atypical Paget's disease with quantitative assessment of tracer kinetics. Clin Nucl Med. 2007;32:765–769
  43. Charkes ND, Todd Makler P, Philips C. Studies of skeletal tracer kinetics. I (Digital computer solution of a five-compartment model of [18F]fluoride kinetics in humans). J Nucl Med. 1978;19:1301–1309
  44. Charkes ND, Brookes M, Todd Makler P. Studies of skeletal tracer kinetics. II (Evaluation of a five-compartment model of [18F]fluoride kinetics in rats). J Nucl Med. 1979;20:1150–1157
  45. Sagar VV, Piccone JM, Charkes ND. Studies of skeletal tracer kinetics. III (Tc99m(Sn)-methylelenediphosophonate uptake in the canine tibia as a function of blood flow). J Nucl Med. 1979;20:1257–1261
  46. Todd Makler P, Charkes ND. Studies of skeletal tracer kinetics IV (Optimum time delay for Tc99m(Sn) methylene disphosphonate bone imaging). J Nucl Med. 1980;21:641–645
  47. Charkes ND, Makler PT. Studies in skeletal tracer kinetics. V (Computer simulated Tc99m(Sn)methylenediphosphonate bone scan changes in certain systemic disorders). J Nucl Med. 1981;22:601–605
  48. Park-Holohan SJ, Blake GM, Fogelman I. Quantitative studies of bone using 18F-fluoride and 99mTc-methylene diphosphonate: Evaluation of renal and whole blood kinetics. Nucl Med Commun. 2001;22:1037–1044
  49. Blake GM, Park-Holohan SJ, Fogelman I. Quantitative studies of bone in postmenopausal women using 18F-fluoride and 99mTc-methylene diphosphonate. J Nucl Med. 2002;43:338–345
  50. Hosking DJ, Chamberlain MJ. Studies in man with 18F. Clin Sci. 1972;42:153–161
  51. Edelman IS, Leibman J. Anatomy of body water and electrolytes. Am J Med. 1959;27:256–277
  52. Moore AE, Park-Holohan SJ, Blake GM, et al. Conventional measurements of GFR using 51Cr-EDTA overestimate true renal clearance by 10%. Eur J Nucl Med. 2003;30:4–8
  53. Moore AE, Blake GM, Fogelman I. Validation of a blood sampling method for the measurement of 99mTc-methylene diphosphonate (99mTc-MDP) plasma clearance. J Nucl Med. 2006;47:581–586
  54. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1–7
  55. Peters AM. Graphical analysis of dynamic data: The Patlak-Rutland plot. Nucl Med Commun. 1994;15:669–672
  56. Moore AE, Blake GM, Taylor K, et al. Skeletal plasma clearance as measured by quantitative radionuclide studies is correlated with bone turnover markers at 3 months of teriparatide therapy. J Bone Miner Res. 2008;23(suppl 1):S121

PII: S0001-2998(09)00040-3

doi: 10.1053/j.semnuclmed.2009.05.001

Seminars in Nuclear Medicine
Volume 39, Issue 6 , Pages 369-379 , November 2009

Article Tools

* Image Usage & Resolution